IL-27 蛋白, Mouse (228a.a, HEK293, His)

IL-27 (Interleukin-27) is a heterodimeric cytokine of the IL-12 family, composed of two subunits, EBI3 (Epstein-Barr-virus-induced molecule 3) and p28^[1]. IL-27 enhances the development, proliferation, and cytotoxic activity of CD8⁺ T cells, thereby indirectly promoting anti-tumor immunity^{[ 2]}. IL-27 Protein, Mouse (228a.a, HEK293, His) is a recombinant protein with a His label that consists of two subunits, EBI3 (IL27B) (228 amino acids (M1-P228)) and IL27A (205 amino acids (F29-S234)), and is produced by HEK293 cells.

IL-27 主要由骨髓来源的细胞（例如单核细胞、巨噬细胞、树突状细胞和小胶质细胞）响应 Toll 样受体或 TNF-R 家族成员的刺激而产生^[3]。
人IL-27蛋白的氨基酸序列与小鼠IL-27蛋白的同源性较低。
IL-27通过由IL-27Rα（WSX1）和gp130链组成的异二聚体受体发挥作用，激活JAK/STAT信号通路，主要涉及STAT1和STAT3磷酸化。IL-27 激活 STAT3 会诱导 SOCS3 的表达，SOCS3 通过抑制 JAK 活性，进一步抑制负反馈环路中的 IL-27 信号传导^[3]。
IL-27 发挥多种作用在促炎和抗炎免疫反应中的作用。IL-27 增强 NF-κB/AP-1 活性，增加 IL-12p40、TNF-α 和 IL-6 的产生，增加 TLR4 和 TLR5 表达^[5]。IL-27对hPMSC的粘附和增殖具有抑制作用，并促进hPMSC的迁移。此外，IL-27 还可上调 PDL1 表达，增强 hPMSC 对 Th1 和 Th2 细胞分化以及 CD4+T 细胞分泌 IL-10 的调节作用^[6]。IL-27 诱导造血干细胞增殖和分化^[7]。IL-27 会增加 IL-10 水平以及 p-STAT1、p-STAT3^[8] 的表达。IL-27 促进 CD4+IL-10+ T 细胞的发育和分化^[9]。

IL-27 (mouse) (1 ng/mL; 7, 14, 21 days) enhances the differentiation of CD34−KSL HSCs^[7].
IL-27 (mouse) (2, 1, 25, 5 ng) increases the expression of p-STAT1, p-STAT3^[8].
IL-27 (mouse) (2 ng/ml) significantly up-regulates the differentiation of CD4+IL-1+ T cells^[9].

IL-27 (mouse) (5, 1 ng; p.o.; daily for 5 days) increases IL-1 levels in the circulation but not in the distal colon in Rag-/- mice ^[8].
IL-27 (mouse) (2 ng/mouse; i.p.; daily for 7 days) up-regulates CD4+IL-1+ T cells and suppress inflammation in NOD mice^[9].

Mouse

HEK293

C-10*His

O35228 (Y19-P228) &GSGSGGSGGSGSGKL& Q8K3I6 (F29-S234)

50498  [NCBI]&246779  [NCBI]

YTETALVALSQPRVQCHASRYPVAVDCSWTPLQAPNSTRSTSFIATYRLGVATQQQSQPCLQRSPQASRCTIPDVHLFSTVPYMLNVTAVHPGGASSSLLAFVAERIIKPDPPEGVRLRTAGQRLQVLWHPPASWPFPDIFSLKYRLRYRRRGASHFRQVGPIEATTFTLRNSKPHAKYCIQVSAQDLTDYGKPSDWSLPGQVESAPHKPGSGSGGSGGSGSGKLFPTDPLSLQELRREFTVSLYLARKLLSEVQGYVHSFAESRLPGVNLDLLPLGYHLPNVSLTFQAWHHLSDSERLCFLATTLRPFPAMLGGLGTQGTWTSSEREQLWAMRLDLRDLHRHLRFQVLAAGFKCSKEEEDKEEEEEEEEEEKKLPLGALGGPNQVSSQVSWPQLLYTYQLLHSLELVLSRAVRDLLLLSLPRRPGSAWDS

Approximately 60 kDa

Greater than 85% as determined by reducing SDS-PAGE

<1 EU/μg, determined by LAL method.

• [1]. [2]Kourko O, et al. IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer. Front Oncol. 2019 Oct 1;9:969.  [Content Brief]

  [2]. Fabbi M, et al. Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediators Inflamm. 2017;2017:3958069.  [Content Brief]

  [3]. Pflanz S, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002 Jun;16(6):779-90.  [Content Brief]

  [4]. Petes C, et al. IL-27 amplifies cytokine responses to Gram-negative bacterial products and Salmonella typhimurium infection. Sci Rep. 2018 Sep 12;8(1):13704.  [Content Brief]

  [5]. Xu F, et al. IL-27 regulates the adherence, proliferation, and migration of MSCs and enhances their regulatory effects on Th1 and Th2 subset generations. Immunol Res. 2017 Aug;65(4):903-912.  [Content Brief]

  [6]. [7]Seita J, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood. 2008 Feb 15;111(4):1903-12.  [Content Brief]

  [7]. Hanson ML, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014 Jan;146(1):210-221.e13.  [Content Brief]

  [8]. Qi J, et al. IL-27 Regulated CD4+IL-10+ T Cells in Experimental Sjögren Syndrome. Front Immunol. 2020 Aug 11;11:1699.  [Content Brief]